Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mindfulness app for anxiety in underserved groups fizzles out early

NCT ID NCT06242080

Symptom relief Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a smartphone app that teaches mindfulness meditation to help Black and Latino adults with anxiety during the COVID-19 pandemic. About 400 participants were assigned to one of two mindfulness programs or a waitlist. The trial was terminated early, so we don't have complete results on whether the app reduced anxiety or improved heart health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mindfulness meditation delivered via a smartphone app
What this could lead to
If it had succeeded, this could have pointed toward a simple, scalable way to reduce anxiety in underserved communities.
What could go wrong
The trial was terminated early, so we don't have clear results. It was also a small, early-stage study focused on a specific group, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

398 people

The number who actually took part.

Started

May 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * self-identify as African American, Black, Hispanic and/or Latino * demonstrate symptoms of anxiety, as determined based on the GAD-7 screening measure (score between 8-14) Exclusion Criteria: * Current, or history of, heart disease * History of stroke or dementia * Diagnosis of movement disorders, such as Parkinson's Disease, or paralysis * Diagnosis of genetic disorders, such as Down Syndrome or Fragile-X syndrome * Diagnosis of autism * Diagnosis of schizophrenia, psychosis, dissociative disorder, mania/bipolar disorder, major depression or a personality disorder * History of serious mental or behavioral health problems requiring a hospital or treatment center stay within the past 12 months * Taking cardiac medications (other than blood pressure medications) * Taking seizure medications * Currently taking opioids medications or supplements * Practice of formal mindfulness for more than 15 minutes/day for 4 or more days/week over the past 6 months * GAD score \<8 or \>14

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety COVID-19 pandemic

Contacts and locations

Locations

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599-7160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.